Related Experiment Video
Updated: Jul 21, 2025
08:43
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
14.8K
Primary Bladder Sarcoma: A multi-institutional experience from the Rare Cancer Network
Piero Bettoli1, ZhihuiAmy Liu2, Natalia Jara3
1Department of Radiation Oncology, Fundación Arturo López Pérez, Santiago; Facultad de Medicina, Universidad de Los Andes, Santiago. piero.bettoli@falp.org.
Summary
Primary bladder sarcoma (SUB) is aggressive, often diagnosed at advanced stages. Local recurrence is common, highlighting the need for multimodal treatment strategies for better patient outcomes.
Area of Science:
- Uro-oncology
- Sarcoma Research
- Cancer Epidemiology
Background:
- Primary sarcoma of the urinary bladder (SUB) is a rare and aggressive malignancy.
- Existing data on SUB is limited, primarily from case reports and small patient series.
- Understanding clinical features, treatment, and outcomes is crucial for improving patient management.
Purpose of the Study:
- To assess the clinical characteristics, treatment modalities, and outcomes of patients diagnosed with primary urinary bladder sarcoma.
- To contribute multi-institutional data to the limited evidence base for SUB.
Main Methods:
- Retrospective multi-institutional study involving 7 centers.
- Data collected from January 1994 to September 2021 using a standardized database.
- Inclusion criteria: bladder cancer with soft tissue tumor histology and sarcomatoid differentiation.
Main Results:
- Fifty-three patients (median age 69 years) were identified; 26% had prior pelvic radiotherapy, 37% were smokers.
- Common symptoms included hematuria (52%) and pelvic pain (27%). Most presented at advanced stages (II-IV).
- Five-year overall survival was 66.5%, progression-free survival (PFS) was 37.6%. Local recurrence (49%) was more common than distant recurrence (37%). No significant difference in PFS across treatment modalities.
Conclusions:
- Primary SUB is a heterogeneous group of tumors, frequently presenting at advanced stages with aggressive behavior.
- Unlike urothelial carcinoma, SUB primarily recurs locally, indicating the necessity for multimodal treatment approaches.
- International collaboration is needed to develop tailored treatment guidelines based on SUB-specific prognostic factors.
